Clinical trial · Observational
Radionecrosis and FDG PET
A Dual Time Point FDG-PET to Differentiate Between Recurrent Brain Tumor and Radionecrosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Gliomas are the most common malignant primary central nervous system (CNS) tumours. When high-grade gliomas (HGG) recur, subsequent magnetic resonance (MRI) imaging, with additional sequences is required.The Positron Emission Tomography (PET) radiotracer \[18F\]-fluorodeoxyglucose (FDG) will be used in this study to distinguish between changes seen on MRI which can be a reflection of pseudoprogression, radiation necrosis, or recurrence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Glioma | Malignant Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Positron Emission Tomography Imaging | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Positron Emission Tomography Imaging
- description
- Dual time point imaging with 250 MBq of 18F-Fluorodeoxyglucose (18F-FDG)
- interventionNames
- Other: Positron Emission Tomography Imaging
Primary outcomes (1)
- measure
- sensitivity and specificity percentages
- timeFrame
- 3 years
- description
- The sensitivity and specificity of dual time point imaging (DTPI) FDG-PET/CT will be compared to the sensitivity and specificity of MR imaging obtained as standard of care for identifying glioma recurrence post-treatment.
Secondary outcomes (1)
- measure
- Cost efficiency analysis
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years old * Able and willing to comply with the study procedures * The patient must be followed at The Ottawa Hospital for a tissue-proven, grade III or IV glioma. * The patient must have been treated in the past with radiotherapy for glioma. * A disease recurrence is suspected based on clinical symptoms and/or imaging results. Exclusion Criteria: * Missing information regarding tumor type and grade * Brain biopsy in the ten days preceding DTPI FDG-PET * Breastfeeding or pregnancy * Claustrophobia or inability to lie still in a supine position * Unwillingness or inability to provide informed consent
References
Publications (0)
Data not yet available